Carbamazepine versus phenobarbitone monotherapy for epilepsy: An individual participant data review

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 10, 2018, Pages

  Nevitt, Sarah J ^a   Marson, Anthony G ^a   Tudur Smith, Catrin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; ANTICONVULSIVE AGENT;

ADVERSE EVENT; EPILEPSY; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; REVIEW; SEIZURE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE TIME; ADULT; CHILD; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GRAND MAL EPILEPSY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; TIME FACTOR;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; EPILEPSY, TONIC-CLONIC; HUMANS; PHENOBARBITAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; SEIZURES; TIME FACTORS; TREATMENT FAILURE;

EID: 85055575408     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001904.pub4     Document Type: Review

References (82)

1. Banu SH, Jahan M, Koli UK, Ferdousi S, Khan NZ, Neville B. Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. BMJ 2007;334(7605):1207. 2671589
2. Bidabadi E. Comparison of the effects of phenobarbital versus carbamazepine as single drug therapy in partial seizure with secondary generalization in children. Epilepsia 2009;50 Suppl 10:167. 2671591
3. Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG. Carbamazepine for epilepsy. A controlled prospective evaluation. Neurology 1974;24(5):401-10. 2671593
4. Cereghino JJ, Brock JT, White BG, Penry JK. Evaluation of carbamazepine in epileptic patients. Neurology 1973;23:433. 9273379
5. Chen YJ, Kang WM, So WC. Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: a psychometric and neurophysiological study. Epilepsia 1996;37(1):81-6. 2671595
6. Cossu G, Monaco F, Piras MR, Grossi E. Short-term therapy with carbamazepine and phenobarbital: effects on cognitive functioning in temporal lobe epilepsy [Trattamento a breve termine con carbamazepina e fenobarbital: effetto sulle funzioni mnesiche nell'epilessia temporale]. Bollettino Lega Italiana contro l'Epilessia 1984;45/46:377-9. 2671597
7. Czapinski P, Terczynski A, Czapinska E. Randomised 36-month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia 1997;38 Suppl(3):42. 2671599
8. de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347(9003):709-13. 2671601
9. Feksi AT, Kaamugisha J, Sander JW, Gatiti S, Shorvon SD. Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group). Lancet 1991;337(16):406-9. 2671603
10. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, or sodium valproate for newly diagnosed epilepsy: a randomized comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry 1995;58(1):44-50. 2671605
11. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 1985;313(3):145-51. 2671607
12. Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 1987;28(Suppl 3):50-8. 9273380
13. Mitchell WG, Chavez JM. Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia 1987;28(1):56-60. 2671609
14. Ogunrin O, Adamolekun B, Ogunniyi A. Cognitive effects of anti-epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences 2005;24(1):18-24. 2671611
15. Placencia M, Sander JW, Shorvon SD, Roman M, Alarcon F, Bimos C, et al. Antiepileptic drug treatment in a community health care setting in northern Ecuador: a prospective 12-month assessment. Epilepsy Research 1993;14(3):237-44. 2671613
16. Bird CA, Griffin BP, Miklaszewska JM, Galbraith AW. Tegretol (carbamazepine): a controlled trial of a new anti-convulsant. British Journal of Psychiatry 1966;112:737-42. 2671615
17. Castro-Gago M, Eiris-Punal J, Novo-Rodriguez MI, Couceiro J, Camina F, Rodriguez-Segade S. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. Journal of Child Neurology 1998;13(11):546-9. 2671617
18. Hansen BS, Dam M, Brandt J, Hvidberg EF, Angelo H, Christensen JM, et al. Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man. Acta Neurologica Scandinavica 1980;61(6):357-67. 2671621
19. Kuzuya T, Hasegawa T, Shimizu K, Nabeshima T. Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. International Journal of Clinical Pharmacology, Therapy, & Toxicology 1993;31(2):61-5. 2671623
20. Marjerrison G, Jedlicki SM, Keogh RP, Hrychuk W, Poulakakis GM. Carbamazepine: behavioral, anticonvulsant and EEG effects in chronically-hospitalized epileptics. Diseases of the Nervous System 1968;29(2):133-6. 2671625
21. Meador KJ, Loring DW, Huh K, Gallagher BB, King DW. Comparative cognitive effects of anticonvulsants. Neurology 1990;40:391-4. 2671627
22. Sabers A, Moller A, Dam M, Smed A, Arlien-Soborg P, Buchman J, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurologica Scandinavica 1995;92(1):19-27. 2671629
23. Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40(4):502-6.
24. Baulac M, Cramer JA, Mattson RH. Phenobarbital and other barbiturates: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al. editor(s). Antiepileptic Drugs. 5th Edition. Philadelphia: Lippincott Williams & Wilkins, 2002:528-40.
25. Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD010236.pub2]
26. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140-4.
27. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22(4):489-501.
28. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389-99.
29. Gruber CM, Brock JT, Dyken MD. Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, dipheylhydantoin, ethotoin, metharbital, and methylphenylhydantion in motor seizures. Clinical Pharmacology and Therapeutics 1962;3:23-8.
30. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 - 1984. Epilepsia 1993;34:453-68.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
32. Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.
33. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders?. Neurology 2007;68:326-37.
34. ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39(7):799-803.
35. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094-120.
36. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313(7048):36-9.
37. Juul-Jenson P, Foldspang A. Natural history of epileptic seizures. Epilepsia 1983;24:297-312.
38. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
39. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine 2000;342:314-9.
40. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
41. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994;35(5):1026-8.
42. MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(Suppl 2):S2-12.
43. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JWA, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology 2000;48:833-41.
44. Malfosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R. Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic. Eastleigh: John Libbey and Company, 1994.
45. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD001030]
46. Matlow J, Koren G. Is carbamazepine safe to take during pregnancy?. Canadian Family Physician 2012;58:163-4.
47. Meador K, Reynolds M, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic reviews and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research 2008;81:1-13.
48. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ 2009;339:2535.
49. Morrow J, Russel A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry 2006;77(2):193-8.
50. Murray CJL, Lopez AD. Global comparative assessments in the health sector. World Health Organization. Geneva, 1994.
51. Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database of Systematic Reviews 2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3]
52. Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3]
53. Nevitt SJ, Tudur Smith C, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 6. [DOI: 10.1002/14651858.CD001031.pub4]
54. Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 8. [DOI: 10.1002/14651858.CD001769.pub4]
55. Nolan SJ, Muller M, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2018, Issue 10. [DOI: 10.1002/14651858.CD003615.pub4]
56. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51:883-90.
57. National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care; Clinical Guidance 137. London: National Institute for Health and Care Excellence, 2012.
58. Nolan SJ, Sutton L, Marson A, Tudur Smith C. Consistency of outcome and statistical reporting of time-to-event data: the impact on Cochrane Reviews and meta-analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health. Quebec City, 2013:114-5.
59. Nolan SJ, Tudur Smith C, Pulman J, Marson AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD002217.pub2]
60. Nolan SJ, Sudell M, Tudur Smith C, Marson A. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD012065.pub2]
61. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorfer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology 2005;4:627-34.
62. Pal DK, Das T, Chaudhury G, Johnson AL, Neville BG. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351(9095):19-23.
63. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
64. Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage dependent inhibition of type hA Nai channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Molecular Pharmacology 1991;40:756-65.
65. Rho JM, Donevan SD, Rogawski MA. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. The Journal of Physiology 1996;497(2):509-22.
66. Sander JW, Shorvon SD. Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61(5):433-43.
67. Sander JW. The use of anti-epileptic drugs - principles and practice. Epilepsia 2004;45(6):28-34.
68. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512-21.
69. Shakir RA. Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants. The place of sodium valproate in the treatment of epilepsy. London: Academic Press Inc (London) Ltd and the Royal Society of Medicine, 1980:7-16.
70. Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33:1487-9.
71. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine 1985;313:916-21.
72. StataCorp LP. Stata Statistical Software. Version release 14. CollegeStation, TX: StataCorp LP, 2015.
73. Trimble MR, Cull C. Children of school age: the influence of antiepileptic drugs on behavior and intellect. Epilepsia 1988;29(Suppl 3):S15-19.
74. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007;5(8):34.
75. Wallace H, Shorvon SD, Hopkins A, O'Donoghue M. Guidelines for the Clinical Management of Adults with Poorly Controlled Epilepsy. London: Royal College of Physicians, 1997.
76. Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews 2016, Issue 11. [DOI: 10.1002/14651858.CD010224.pub2]
77. Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick DW. Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. Journal of Evaluation in Clinical Practice 2000;6(2):205-14.
78. Williamson PR, Tudur Smith C, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(11):3337-51.
79. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD001904.pub2]
80. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub3]
81. Tudur C, Marson AG, Williamson PR, Hutton JL, Chadwick DW. Carbamazepine vs phenobarbitone monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD001904]
82. Tudur Smith C, Marson AG, Williamson PR. Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001904]